Response to Tyrosine Kinase Inhibitors in Patients with BCR-ABL1 Positive Chronic Myeloid Leukemia; 13.5 Years’ Experience at Patan Hospital, Nepal
A. Adhikari, K. Shrish, G. K. Kayastha, N. Ranjitkar, M. Zimmerman, M. Lama, R. K. Thapa & B. Basnyat · International Blood Research & Reviews · 2023
Background: Since the advent of Tyrosine Kinase Inhibitor (TKI), well controlled studies in developed world have shown that the life expectancy of patients with CML is comparable to normal people without the disease. But long-term follow up studies are lacking in resource poor se...
Open access
Research Article
10.9734/ibrr/2023/v14i2301